Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05BJD
|
|||
| Former ID |
DAP001406
|
|||
| Drug Name |
Motexafin gadolinium
|
|||
| Synonyms |
Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Brain cancer [ICD-11: 2A00] | Approved | [1] | |
| Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 3 | [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Pharmacyclics, Inc
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C52H72GdN5O14
|
|||
| Canonical SMILES |
CCC1=C(C2=CC3=NC(=CN=C4C=C(C(=CC4=NC=C5C(=C(C(=N5)C=C1[N-]2)CCCO)C)OCCOCCOCCOC)OCCOCCOCCOC)C(=C3CCCO)C)CC.CC(=O)[O-].CC(=O)[O-].[Gd+3]
|
|||
| InChI |
1S/C48H66N5O10.2C2H4O2.Gd/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);/q-1;;;+3/p-2
|
|||
| InChIKey |
VAZLWPAHMORDGR-UHFFFAOYSA-L
|
|||
| CAS Number |
CAS 246252-06-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thioredoxin reductase (PRDX5) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium. Catheter Cardiovasc Interv. 2002 Nov;57(3):387-94. | |||
| REF 2 | Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem Biophys Res Commun. 2009 Feb 13;379(3):775-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.